Improvement in Chronic Atrophic Gastritis After Treatment with Zinc L-Carnosine.
Level 4 - case-series / case-control
Case series of two patients without a control group
PubMed 41264559 · doi:10.12659/AJCR.950553
What was done
Two patients with chronic atrophic gastritis (CAG)—one secondary to autoimmune gastritis and the other secondary to Helicobacter pylori infection—were treated with oral zinc L-carnosine (39.5 mg twice daily) for at least 12 months for persistent dyspeptic symptoms. Endoscopic evaluation, histologic reassessment, and gastric biomarker testing (pepsinogen I, pepsinogen II, and gastrin 17) were conducted after at least 12 months of treatment.
What was found
The authors report clinically significant improvements in dyspeptic symptoms, histologic features of chronic atrophic gastritis, and gastric function biomarkers (pepsinogen I, pepsinogen II, and gastrin 17) in both patients. The abstract provides no specific numerical values, baseline scores, or magnitude of changes.
Why it matters
This report provides preliminary clinical observation that zinc L-carnosine may improve symptoms and mucosal features in chronic atrophic gastritis.
Limits
The study is an uncontrolled case series of only two patients (n = 2), precluding any definitive causal inference. The abstract reports no quantitative data, and the design lacks blinding, controls, and long-term clinical outcome follow-up.
Cited by
- partial Zinc L-carnosine is an effective treatment or supportive supplement for chronic gastritis.